Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01698-7
Abstract: Background Sorafenib is a current first-line treatment option for advanced hepatocellular carcinoma (HCC). This study aimed to evaluate the impact of early adverse events (AEs) requiring sorafenib dose adjustment on survival outcomes of patients with… read more here.
Keywords: hepatocellular carcinoma; survival outcomes; sorafenib; sorafenib dose ... See more keywords
Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study
Sign Up to like & getrecommendations! Published in 2017 at "BJU International"
DOI: 10.1111/bju.13740
Abstract: To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC). read more here.
Keywords: renal cell; dose escalation; cell carcinoma; sorafenib dose ... See more keywords